Boosting a Natural Brain Cannabinoid Delayed Seizure Development in Mice
Blocking the enzyme that breaks down the endocannabinoid 2-AG slowed the progression of seizure development in a mouse model of epilepsy, but had minimal effect once seizures were established.
Quick Facts
What This Study Found
Researchers tested whether increasing levels of the brain's own cannabinoid 2-AG, by blocking the enzyme MAGL that normally breaks it down, could slow epilepsy development in mice.
Using JZL184, a MAGL inhibitor, they found it significantly delayed the progression from mild to generalized seizures in the kindling model of temporal lobe epilepsy. Seizure duration and afterdischarge duration were both reduced during the kindling process.
However, once mice were fully kindled (seizures fully established), JZL184 had only modest effects. The anti-seizure effects disappeared in mice genetically engineered to lack CB1 receptors in forebrain neurons, confirming the drug worked through the cannabinoid system.
Key Numbers
JZL184 at 8 mg/kg significantly delayed generalized seizure development (p=0.0066). Seizure duration was reduced (p<0.0001). Afterdischarge duration decreased (p<0.001). Effects were absent in CB1 receptor knockout mice.
How They Did This
Mice received JZL184 (8 mg/kg) or vehicle before kindling stimulations. Researchers tracked seizure severity scores, seizure duration, and afterdischarge duration. Conditional CB1 receptor knockout mice were used to confirm mechanism. The kindling model progressively induces seizures through repeated electrical stimulation.
Why This Research Matters
Most epilepsy drugs manage existing seizures but do not prevent epilepsy from developing. This study suggests that boosting endocannabinoid signaling could potentially slow or prevent epilepsy development, which would represent a fundamentally different treatment approach.
The Bigger Picture
This study adds to growing evidence that the endocannabinoid system plays a role in seizure regulation. Rather than directly activating cannabinoid receptors (like THC does), boosting naturally produced cannabinoids at sites of excessive brain activity could offer a more targeted approach with potentially fewer side effects.
What This Study Doesn't Tell Us
The kindling model is one of several epilepsy models and may not fully represent human epilepsy. Results from mice do not directly translate to humans. The drug showed limited benefit once seizures were already established, and long-term effects were not studied.
Questions This Raises
- ?Could MAGL inhibitors prevent epilepsy development in humans after a brain injury or other trigger?
- ?Would combining MAGL inhibition with existing anti-seizure medications improve outcomes?
Trust & Context
- Key Stat:
- Seizure development was significantly delayed (p=0.0066) by boosting 2-AG levels
- Evidence Grade:
- This is an animal study in mice. While the results are compelling, they require replication and eventual testing in humans before clinical relevance can be determined.
- Study Age:
- Published in 2015. Research on endocannabinoid-based approaches to epilepsy has continued to advance, particularly with the approval of CBD-based medications.
- Original Title:
- Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice.
- Published In:
- Neurobiology of disease, 77, 238-45 (2015)
- Authors:
- von Rüden, E L, Bogdanovic, R M, Wotjak, C T, Potschka, H
- Database ID:
- RTHC-01072
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Is this the same thing as using CBD for seizures?
No. This study targeted a different part of the endocannabinoid system by blocking the enzyme that breaks down 2-AG, rather than using CBD or THC directly. CBD works through multiple mechanisms that are distinct from MAGL inhibition.
Could this approach prevent epilepsy rather than just treat it?
That is one implication of the findings. The drug slowed seizure development but had minimal effect on established seizures, which suggests potential for preventive rather than acute treatment. However, this has only been shown in mice.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01072APA
von Rüden, E L; Bogdanovic, R M; Wotjak, C T; Potschka, H. (2015). Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice.. Neurobiology of disease, 77, 238-45. https://doi.org/10.1016/j.nbd.2015.03.016
MLA
von Rüden, E L, et al. "Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice.." Neurobiology of disease, 2015. https://doi.org/10.1016/j.nbd.2015.03.016
RethinkTHC
RethinkTHC Research Database. "Inhibition of monoacylglycerol lipase mediates a cannabinoid..." RTHC-01072. Retrieved from https://rethinkthc.com/research/von-2015-inhibition-of-monoacylglycerol-lipase
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.